Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065633 | 0.85 | ALDH1A1 (0.51) | ALDH1A1FFAR1MEN1KMT2ANPC1 | |
| SCHEMBL1027884 | 0.75 | MEN1 (0.47) | ALDH1A1FFAR1MEN1KMT2ANPC1 | |
| SCHEMBL2881402 | 0.75 | PPARA (0.49) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4147783 | 0.75 | ESRRG (0.49) | ALDH1A1MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL1935310 | 0.75 | MEN1 (0.47) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21247482 | 0.75 | KMT2A (0.63) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27925889 | 0.75 | ALDH1A1 (0.53) | ALDH1A1FFAR1MEN1KMT2ANPC1 | |
| SCHEMBL17044875 | 0.74 | HCAR2 (0.39) | MEN1KMT2ALMNAL3MBTL1HTT | |
| SCHEMBL21997106 | 0.74 | KMT2A (0.46) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1845384 | 0.74 | MEN1 (0.46) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | ALDH1A1 3099/4885FFAR1 4653/4885MEN1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.